Celfex AB
Celfex AB is a subsidiary of MHG Management GmbH – as Swiss based pharma company.
Celfex AB has a focus on the development of Atopic Dermatitis IP which has been sub-licensed from MHG Management GmbH.
Celfex AB has organized itself in a way which will drive cost effective and accelerated development of our licensed intellectual property. We collaborate with our parent company, with CRO partners and advisors to manage overhead risk and leverage best practices.
Result = Value to Patients
Return to Inventor + Return to Investor + Return to Collaborators
